The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
|Articles|September 1, 2003
Smallpox Tops List of Bioterror Agents
Author(s)Paula Moyer
San Francisco - As the international situation has become more complicated, dermatologists have realized that they may need to diagnose and respond to individuals who have been infected by a microbial agent of bioterrorism. Among the several viral agents that could be so used, smallpox has caused the greatest concern, according to Scott A. Norton, M.D., M.P.H., M.Sc.
Advertisement
Advertisement
Related to this article
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
New review explores why eczema and ADHD often overlap in youth, highlighting sleep loss, itch-driven inflammation, plus screening and treatment tips.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
Alopecia Areata Awareness Month: 2026 in Review
3
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
4
Dermatology Times Spot Test: September 27, 2026
5